XEL 1000

Drug Profile

XEL 1000

Latest Information Update: 21 Dec 2015

Price : $50

At a glance

  • Originator Xellia Pharmaceuticals
  • Class Antibacterials
  • Mechanism of Action Cell membrane modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Clinical Phase Unknown Cystic fibrosis-associated respiratory tract infections

Most Recent Events

  • 21 Dec 2015 Clinical trials in Cystic fibrosis-associated respiratory tract infections in Norway (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top